STM-416 Immunotherapy for Recurrent Bladder Cancer

Principal Investigator: Jed Ferguson

Bladder cancer has one of the highest recurrence rates of any cancer, often requiring repeated surgeries and lifelong monitoring. This study explores a new localized immunotherapy approach designed to strengthen the body’s immune response directly within the bladder. If successful, STM-416 could offer a new treatment strategy for patients with recurrent bladder cancer while potentially reducing the need for more invasive interventions.

Researchers at the Birmingham VA are participating in a first-in-human Phase 1/2a clinical trial evaluating an investigational immunotherapy called STM-416 for patients with recurrent high-grade non–muscle-invasive bladder cancer (NMIBC). The study is focused on determining whether STM-416 can safely reduce the risk of bladder cancer recurrence after surgical tumor removal.

Non–muscle-invasive bladder cancer is a form of bladder cancer that has not spread into the bladder muscle but carries a high risk of returning after treatment. Standard treatment often involves transurethral resection of bladder tumor (TURBT) surgery followed by bladder-directed therapies such as Bacillus Calmette-Guérin (BCG) immunotherapy. However, recurrence rates remain significant, and some patients either do not respond adequately or cannot tolerate available treatments.

STM-416 is a hydrogel-based formulation of resiquimod, an immune-activating compound that stimulates Toll-like receptors 7 and 8 (TLR7/8). The treatment is administered directly into the bladder during TURBT surgery, where the hydrogel is designed to slowly release the medication over time. Researchers hope this localized immune activation will help the body recognize and destroy remaining cancer cells while minimizing systemic side effects.

This multicenter study includes both dose-escalation and dose-expansion phases to evaluate safety, tolerability, and early signs of effectiveness. Participants are monitored through cystoscopy exams, urine testing, and follow-up visits over an extended period to assess recurrence and progression rates.

Earlier research involving related intravesical immune therapies has shown encouraging safety profiles and evidence of immune activation in bladder cancer patients. Researchers are particularly interested in whether newer immunotherapy strategies like STM-416 may improve long-term bladder preservation and reduce recurrence in patients with high-risk disease.

ClinicalTrials.gov ID: NCT05710848